Big endothelin-1 is not a predictor in aortic stenosis, but is related to arterial blood pressure

International Journal of Cardiology

Volumn 113, Issue 2, 2006, Pages 174-180

  Bergler Klein, Jutta ^a   Klaar, Ursula ^a   Heger, Maria ^a   Rosenhek, Raphael ^a   Gabriel, Harald ^a   Binder, Thomas ^a   Pacher, Richard ^a   Maurer, Gerald ^a   Baumgartner, Helmut ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aortic stenosis; Big endothelin 1; Neurohormones

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; AORTA PRESSURE; AORTA STENOSIS; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE SEPTUM; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SURVIVAL; SYMPTOM; SYSTOLIC BLOOD PRESSURE;

AGED; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 33750484305     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.11.008     Document Type: Article

References (45)

1. Carabello B.A. Clinical practice. Aortic stenosis. N Engl J Med 346 (2002) 677
2. Bonow R.O., Carabello B., de Leon Jr. A.C., et al. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32 (1998) 1486-1588
3. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
4. Iung B., Gohlke-Barwolf C., Tornos P., et al. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 23 (2002) 1253-1266
5. Rosenhek R., Maurer G., and Baumgartner H. Should early elective surgery be performed in patients with severe but asymptomatic aortic stenosis?. Eur Heart J 23 18 (2002) 1417-213
6. McCann G.P., and Hillis W.S. Surgery in asymptomatic aortic stenosis. BMJ 328 (2004) 63-64
7. Pellikka P.A., Nishimura R.A., Bailey K.R., et al. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 15 (1990) 1012-1017
8. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic and exercise predictors of outcome. Circulation 95 (1997) 2262-2270
9. Orsinelli D.A., Aurigemma G.P., Battista S., et al. Left ventricular hypertrophy and mortality after aortic valve replacement for aortic stenosis: a high risk subgroup identified by preoperative relative wall thickness. J Am Coll Cardiol 22 (1993) 1679
10. Hammermeister K., Sethi G.K., Henderson W.G., et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 36 4 (2000) 1152-1158
11. Richard A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
12. Stanek B., Frey B., Hülsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
13. Ikeda T., Matsuda K., Itoh H., et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 133 (1997) 307-314
14. Talwar S., Downie P.F., Squire I.B., et al. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 3 (2001) 15-19
15. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 4 (2001) 725-732
16. Gerber I.L., Stewart R.A.H., Legget M.E., et al. Increased plasma natriuretic peptides reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
17. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 19 (2004 (May 18)) 2302-2308
18. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in severe aortic stenosis with normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25 (2004) 2048-2053
19. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
20. Wei C.M., Lerman, and Rodeheffer R.J. Endothelin in human congestive heart failure. Circulation 89 (1994) 1580-1586
21. Pacher R., Bergler-Klein J., Globits S., et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 71 (1993) 1293-1299
22. Kiowski W., Sütsch G., Hunziker P., et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 346 (1995) 732-736
23. Pacher R., Stanek B., Huelsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27 (1996) 633-641
24. Hulsmann M., Stanek B., Frey B., et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32 (1998) 1695-1700
25. Stanek B., Frey B., Hulsmann M., et al. Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 29 (1997) 595-596
26. Bergler-Klein J., Pacher R., Berger R., Bojic A., and Stanek B. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant 23 1 (2004) 20-27
27. Serneri G.G., Modesti P.A., Boddi M., et al. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 85 1 (1999) 57-67
28. Patel D.N., and Bailey S.R. Role of BNP in patients with severe asymptomatic aortic stenosis. Eur Heart J 25 (2004) 1972-1973
29. Omland T., Terje Lie R., Aakvaag A., Aarsland T., and Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89 (1994) 1573-1579
30. Wagner O.F., Christ G., Wojta J., et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267 23 (1992) 16066-16068
31. Perez del Villar C., Garcia Alonso C.J., Feldstein C.A., Juncos L.A., and Romero J.C. Role of endothelin in the pathogenesis of hypertension. Mayo Clin Proc 80 1 (2005) 84-96
32. Ramirez-Gil J.F., Drobinski G., Carayon A., et al. Neurohormonal profile in aortic valve stenosis. Arch Mal Coeur Vaiss 86 7 (1993) 1001-1007
33. Hrudova J., Linhart A., Vondracek V., et al. Humoral profile of patients with severe aortic stenosis. Cas Lek Cesk 139 3 (2000) 74-78
34. Dupuis J. Increased endothelin levels in congestive heart failure: does it come from the lungs? Does it matter?. Cardiovasc Res 63 1 (2004) 5-7
35. Schiffrin E.L. Endothelin and endothelin antagonists in hypertension. J Hypertens 16 12 Pt 2 (1998) 1891-1895
36. Cardillo C., Campia U., Iantorno M., and Panza J.A. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43 (2004) 36-40
37. Seo B., Oemar B.S., Siebenmann R., von Segesser L., and Lüscher T.F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89 (1994) 1203-1208
38. Abdel-Sayed S., Nussberger J., Aubert J.F., Gohlke P., Brunner H.R., and Brakch N. Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. Am J Hypertens (2003) 515-521
39. Vierhapper H., Wagner O., Nowotny P., and Waldhäusl W. Effect of endothelin-1 in man. Circulation 81 (1990) 1415-1418
40. Lavallee M., Takamura M., Parent R., and Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 6 (2001) 265-276
41. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V., and Bosentan Hypertension Investigators. The effect of an endothelin-receptor antagonist bosentan on blood pressure in patients with essential hypertension. N Engl J Med 338 (1998) 784-790
42. Lerman A., Edwards B.S., Hallett J.W., Heublein D.M., Sandberg S.M., and Burnett J.J. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325 (1991) 997-1001
43. Wenzel R.R., Fleisch M., Shaw S., et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98 21 (1998) 2235-2240
44. Jensen L.W., Bagger J.P., and Pedersen E.B. Twenty-four-hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Blood Press 5 5 (1996) 292-299
45. Kammerl M.C., Grimm D., Kromer E.P., et al. Effects of aortic stenosis on renal renin, angiotensin receptor, endothelin and NOS gene expression in rats. Am J Nephrol 22 1 (2002) 84-89